Abstract

BACKGROUND: Two significant changes in the management of ependymoma have taken place since 1990 at The Hospital for Sick Children, Toronto; the up-front irradiation of infants and the re-irradiation of recurrent disease. This study retrospectively reviews the impact of these changes on survival. METHODS: A retrospective case note analysis of children treated for ependymoma between 1990 and 2014 was undertaken. Survival was determined using the Kaplan Meier method. RESULTS: 76 ependymoma patients were identified with a median age of 4.58 years (0.42-17.6) including 31 infants < 3 years old (median age 1.51 years (0.42-2.97)). 45 (59.2%) were male and 31 (40.8%) were female. The majority (56 (73.7%)) were grade III histology and most (56 (73.7%)) were located within the posterior fossa. The median progression free survival (PFS) and overall survival (OS) was 41 months (95% CI 20.4-61.7) and 116 months (95% CI 63.5-169.4) respectively. 5 year PFS and OS were 43.3% and 59.3% respectively. 21 infants received up-front radiation and 10 received chemotherapy only. 5 year PFS and OS were significantly higher in irradiated compared to non-irradiated infants (PFS: 52.9% versus 0% (p = 0.000002), OS: 74.6% versus 30.0% (p = 0.004)). 38 patients recurred of which 26 were previously irradiated.19 patients received re-irradiation on recurrence whereas 7 did not. 5 year OS was significantly higher in the re-irradiated patients at 71.8% compared to 0% in the non re-irradiated patients (p = 0.00007). Both management strategies were consistently implemented from 2004. Patients treated pre (n = 34) and post (n = 42) 2004 showed a significant improvement in 5 year PFS from 33.4% to 53.3% (p = 0.037) and OS from 51.2% to 79.2% (p = 0.02). CONCLUSIONS: Both radiation of infants as the initial management of ependymoma and re-irradiation of recurrent ependymoma significantly improve survival. Implementing these treatment strategies has resulted in significant improvement in progression free and overall survival for ependymoma patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call